QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 watching-lantern-pharma-zacks-small-cap-research-gives-stock-26-price-valuation

https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08122024_LTRN_Vandermosten.pdf

 lantern-pharma-q2-2024-gaap-eps-046-beats-055-estimate

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.55...

 lantern-pharma-shares-clinical-update-from-ongoing-phase-2-harmonic-clinical-trial-for-never-smokers-with-advanced-nsclc-including-an-86-clinical-benefit-rate-in-the-initial-patient-cohort

The Phase 2 HARMONIC™ study is designed for never smokers with lung adenocarcinoma with the objective to overcome driver mutati...

 lantern-pharma-achieves-milestone-towards-development-of-molecular-diagnostic-for-use-in-oncology-clinical-trials-for-patient-selection-and-stratification-with-drug-candidate-lp-184--confirmed-ptgr1-as-a-key-biomarker-that-it-intends-to-use-to-optimize-patient-selection-based-on-potential-tumor-sensitivity-to-the-drug-candidate-lp-184

Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine le...

 lantern-pharma-q1-2024-gaap-eps-051-misses-043-estimate

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0....

 oregon-therapeutics--lantern-pharma-launch-strategic-ai-collaboration-to-optimize-development-of-first-in-class-drug-candidate-xce853--a-potent-inhibitor-of-cancer-metabolism

Lantern Pharma Inc. (NASDAQ:LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, toda...

 hc-wainwright--co-reiterates-neutral-on-lantern-pharma

HC Wainwright & Co. analyst Emily Bodnar reiterates Lantern Pharma (NASDAQ:LTRN) with a Neutral.

 lantern-pharma-approved-to-expand-harmonic-clinical-trial-for-non-small-cell-lung-cancer-in-never-smokers-into-japan-and-taiwan

never smokers – a growing and unaddressed patient population.Dr. Yashushi Goto a leading lung cancer clinician-scientist at the...

 recap-lantern-pharma-q4-earnings
Recap: Lantern Pharma Q4 Earnings
03/18/2024 20:30:21

 lantern-pharma-q4-2023-gaap-eps-039-beats-048-estimate

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.48...

 earnings-scheduled-for-march-18-2024

Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION